Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Bimzelx Prior Auth Policy | OpenPayer
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 6220-A

    Specialty Guideline Management Bimzelx

    Customize your policy alerts

    Sign up for cvs_caremark Policy 6220-A alerts

    Get alerted when Policy 6220-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization requirements for Bimzelx in adult members with moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, or hidradenitis suppurativa.

    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Bimzelx
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit documentation to initiate prior authorization review for Bimzelx.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5FDA-approved covered indications
    12 monthsAuthorization duration
    10% BSAPlaque psoriasis threshold
    8 weeksHidradenitis antibiotic trial
    TB evaluationPre-treatment safety

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Universal requirements

    Coverage Criteria

    Initial therapy - plaque psoriasis

    Covered for adult members with moderate to severe plaque psoriasis when any applicable initial pathway is met.

    Initial plaque psoriasis pathways

    • Prior biologic or targeted synthetic therapy: Previously received a biologic or targeted synthetic drug indicated for moderate to severe plaque psoriasis, such as Sotyktu or Otezla.
    • Disease-severity criteria

      • Crucial body areas: Hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas are affected.
      • Extensive disease: At least 10% of body surface area is affected.At least 10% BSA
      • Limited BSA with failed or unsuitable conventional therapy: At least 3% of body surface area is affected and the member has either an inadequate response or intolerance to phototherapy or methotrexate, cyclosporine, or acitretin, or a clinical reason to avoid methotrexate, cyclosporine, and acitretin.At least 3% BSA

    Initial therapy - psoriatic arthritis

    Covered for adult members with active psoriatic arthritis when any applicable initial pathway is met.

    Initial psoriatic arthritis pathways

    • Prior biologic or targeted synthetic therapy: Previously received a biologic or targeted synthetic drug indicated for active psoriatic arthritis, such as Rinvoq or Otezla.
    • Disease and treatment criteria

      • Mild to moderate disease with inadequate response: Mild to moderate disease and inadequate response to methotrexate, leflunomide, or another conventional synthetic drug such as sulfasalazine administered at an adequate dose and duration.
      • Mild to moderate disease with intolerance or contraindication: Mild to moderate disease and intolerance or contraindication to methotrexate, leflunomide, or another conventional synthetic drug such as sulfasalazine.

    Initial therapy - ankylosing spondylitis and non-radiographic axial spondyloarthritis

    Covered for adult members with active ankylosing spondylitis or active non-radiographic axial spondyloarthritis when any applicable initial pathway is met.

    Initial axial spondyloarthritis pathways

    • Prior biologic or targeted synthetic therapy: Previously received a biologic or targeted synthetic drug indicated for active ankylosing spondylitis or active non-radiographic axial spondyloarthritis, such as Rinvoq or Xeljanz.
    • NSAID treatment criteria

      • NSAID inadequate response: Inadequate response to at least two nonsteroidal anti-inflammatory drugs.At least two NSAIDs
      • NSAID intolerance or contraindication: Intolerance or contraindication to two or more nonsteroidal anti-inflammatory drugs.

    Initial therapy - hidradenitis suppurativa

    Covered for adult members with moderate to severe hidradenitis suppurativa when any applicable initial pathway is met.

    Initial hidradenitis suppurativa pathways

    • Prior biologic therapy: Previously received a biologic indicated for treatment of moderate to severe hidradenitis suppurativa.
    • Oral-antibiotic criteria

      • Oral-antibiotic inadequate response: Inadequate response to an oral antibiotic used for hidradenitis suppurativa for at least 8 weeks, such as clindamycin, metronidazole, moxifloxacin, rifampin, or a tetracycline.At least 8 weeks
      • Oral-antibiotic intolerance or contraindication: Intolerance or contraindication to oral antibiotics used for hidradenitis suppurativa.

    Continuation therapy - plaque psoriasis

    Continuation authorization may be granted for 12 months when positive response is demonstrated.

    Plaque psoriasis continuation: The member is an adult, including a new member, using Bimzelx for moderate to severe plaque psoriasis and achieves or maintains low disease activity or improvement in signs and symptoms, with either a reduction in BSA affected from baseline or improvement in signs and symptoms from baseline, including itching, redness, flaking, scaling, burning, cracking, or pain.

    Continuation therapy - psoriatic arthritis

    Continuation authorization may be granted for 12 months when positive response is demonstrated.

    Psoriatic arthritis continuation: The member is an adult, including a new member, using Bimzelx for psoriatic arthritis and achieves or maintains low disease activity or improvement in signs and symptoms, with improvement from baseline in any of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, skin or nail involvement, functional status, or C-reactive protein.

    Continuation therapy - ankylosing spondylitis and non-radiographic axial spondyloarthritis

    Continuation authorization may be granted for 12 months when positive response is demonstrated.

    Axial spondyloarthritis continuation: The member is an adult, including a new member, using Bimzelx for ankylosing spondylitis or non-radiographic axial spondyloarthritis and achieves or maintains low disease activity or improvement in signs and symptoms, with improvement from baseline in any of the following: functional status, total spinal pain, inflammation such as morning stiffness, swollen joints, tender joints, or C-reactive protein.

    Continuation therapy - hidradenitis suppurativa

    Continuation authorization may be granted for 12 months when positive response is demonstrated.

    Hidradenitis suppurativa continuation: The member is an adult, including a new member, using Bimzelx for moderate to severe hidradenitis suppurativa and achieves or maintains low disease activity or improvement in signs and symptoms, with any of the following: reduction in abscess and inflammatory nodule count, reduced formation of new sinus tracts and scarring, decreased frequency of inflammatory lesions, reduced pain or suppuration, improved frequency of relapses, improved quality of life, or improvement on a disease severity assessment tool.

    Universal requirements for all indications

    For all indications, both requirements must be met.

    Universal requirements

    • TB evaluation: The member has been evaluated for tuberculosis infection before initiation of treatment with a biologic or targeted synthetic drug associated with an increased risk of TB.
    • No concomitant same-indication therapy: The requested medication is not used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    Use of Bimzelx for indications other than the listed FDA-approved indications is considered experimental, investigational, and not medically necessary.

    Bimzelx cannot be used concurrently with another biologic drug or targeted synthetic drug for the same indication.

    Concomitant use of the requested medication with any other biologic drug or targeted synthetic drug for the same indication is excluded.

    Coverage is limited to adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy; active psoriatic arthritis; active non-radiographic axial spondyloarthritis with objective signs of inflammation; active ankylosing spondylitis; or moderate to severe hidradenitis suppurativa. All other indications are considered experimental, investigational, and not medically necessary.

    Initial Therapy Criteria

    Plaque psoriasis initial therapy

    Authorization of 12 months may be granted for adult members with moderate to severe plaque psoriasis when any one of the following pathways is met.

    Plaque psoriasis initial pathways

    • Prior therapy: Previously received a biologic or targeted synthetic drug indicated for moderate to severe plaque psoriasis, such as Sotyktu or Otezla.
    • Disease-severity pathway

      • Crucial body areas: Hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas are affected.
      • Extensive disease: At least 10% of body surface area is affected.

    Continuation Criteria

    Plaque psoriasis continuation

    Authorization of 12 months may be granted for adult members, including new members, using Bimzelx for moderate to severe plaque psoriasis who achieve or maintain a positive clinical response.

    Plaque psoriasis continuation response: The member achieves or maintains low disease activity or improvement in signs and symptoms, with either a reduction in body surface area affected from baseline or improvement in signs and symptoms from baseline, including itching, redness, flaking, scaling, burning, cracking, or pain.

    Psoriatic arthritis continuation

    Authorization of 12 months may be granted for adult members, including new members, using Bimzelx for psoriatic arthritis who achieve or maintain a positive clinical response.

    Psoriatic arthritis continuation response: The member achieves or maintains low disease activity or improvement in signs and symptoms, with improvement from baseline in any of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, skin or nail involvement, functional status, or C-reactive protein.

    Prior Therapy Requirements

    Step therapy pathwayCriteria
    Prior biologic or targeted synthetic therapyPreviously received a biologic or targeted synthetic drug indicated for moderate to severe plaque psoriasis, such as Sotyktu or Otezla.
    Disease severity or locationCrucial body areas are affected, including the hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas.
    Extensive diseaseAt least 10% of body surface area (BSA) is affected.
    Limited BSA with failed or unsuitable conventional therapyAt least 3% of BSA is affected and the member has an inadequate response or intolerance to phototherapy or methotrexate, cyclosporine, or acitretin, or has a clinical reason to avoid methotrexate, cyclosporine, and acitretin.
    Step therapy pathwayCriteria
    Prior biologic or targeted synthetic therapyPreviously received a biologic or targeted synthetic drug indicated for active psoriatic arthritis, such as Rinvoq or Otezla.
    Conventional synthetic drug: inadequate responseMild to moderate disease with an inadequate response to methotrexate, leflunomide, or another conventional synthetic drug, such as sulfasalazine, administered at an adequate dose and duration.
    Conventional synthetic drug: intolerance or contraindicationMild to moderate disease with intolerance or contraindication to methotrexate, leflunomide, or another conventional synthetic drug, such as sulfasalazine.
    Enthesitis or predominantly axial diseaseMild to moderate disease with enthesitis or predominantly axial disease.
    Severe diseaseThe member has severe disease.
    Step therapy pathwayCriteria
    Prior biologic or targeted synthetic therapyPreviously received a biologic or targeted synthetic drug indicated for active ankylosing spondylitis or active non-radiographic axial spondyloarthritis, such as Rinvoq or Xeljanz.
    NSAID trial: inadequate responseInadequate response to at least two nonsteroidal anti-inflammatory drugs (NSAIDs).
    NSAID avoidance pathwayIntolerance or contraindication to two or more NSAIDs.
    Step therapy pathwayCriteria
    Prior biologic therapyPreviously received a biologic indicated for treatment of moderate to severe hidradenitis suppurativa.
    Oral-antibiotic trialInadequate response to an oral antibiotic used for hidradenitis suppurativa for at least 8 weeks, such as clindamycin, metronidazole, moxifloxacin, rifampin, or a tetracycline.
    Oral-antibiotic avoidance pathwayIntolerance or contraindication to oral antibiotics used for treatment of hidradenitis suppurativa.

    Clinical Thresholds and Treatment History

    Plaque psoriasis body surface area
    Standard BSA thresholdAt least 10% of body surface area (BSA) is affected.
    Lower BSA thresholdAt least 3% BSA is affected, with a qualifying treatment-history or avoidance criterion.
    Treatment response or intoleranceInadequate response or intolerance to phototherapy or treatment with methotrexate, cyclosporine, or acitretin.
    Treatment avoidanceA clinical reason to avoid treatment with methotrexate, cyclosporine, and acitretin.
    Crucial body areasCoverage may also qualify when crucial areas are affected, including the hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas.
    Hidradenitis suppurativa oral-antibiotic trial

    Authorization, Documentation, and Safety Requirements

    Prior Authorization

    Initial Authorization: 12-Month Approval

    Prior authorization may be approved for 12 months for adult members when the applicable indication-specific initial criteria are met, including required prior therapy and disease-specific clinical criteria.

    • Covered indications: moderate to severe plaque psoriasis, active psoriatic arthritis, active ankylosing spondylitis or non-radiographic axial spondyloarthritis, and moderate to severe hidradenitis suppurativa.
    Prior Authorization

    Continuation Authorization: 12-Month Approval

    Continuation authorization may be approved for 12 months for all adult members, including new members, who are using Bimzelx for a covered indication and achieve or maintain a positive clinical response.

    • The response must be supported by improvement in indication-specific signs, symptoms, disease activity, or functional measures from baseline.

    Policy Background

    Bimzelx (bimekizumab-bkzx) is a biologic therapy covered under this guideline for selected adult inflammatory dermatologic and rheumatologic conditions. Covered conditions include plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa. Coverage is subject to indication-specific criteria and required safety conditions.

    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Bimzelx
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit documentation to initiate prior authorization review for Bimzelx.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation CriteriaPrior Therapy RequirementsClinical Thresholds and Treatment HistoryAuthorization, Documentation, and Safety RequirementsPolicy Background
    Enthesitis or axial disease: Mild to moderate disease with enthesitis or predominantly axial disease.
  1. Severe disease: The member has severe disease.
  2. Two or more NSAIDs
    At least 10% BSA
  3. Limited BSA and failed or unsuitable therapy: At least 3% of body surface area is affected and the member has inadequate response or intolerance to phototherapy or methotrexate, cyclosporine, or acitretin, or has a clinical reason to avoid methotrexate, cyclosporine, and acitretin.At least 3% BSA
  4. Psoriatic arthritis initial therapy

    Authorization of 12 months may be granted for adult members with active psoriatic arthritis when any one of the following pathways is met.

    Psoriatic arthritis initial pathways

    • Prior therapy: Previously received a biologic or targeted synthetic drug indicated for active psoriatic arthritis, such as Rinvoq or Otezla.
    • Disease and treatment pathway

      • Mild to moderate disease with inadequate response: Mild to moderate disease and inadequate response to methotrexate, leflunomide, or another conventional synthetic drug such as sulfasalazine administered at an adequate dose and duration.
      • Mild to moderate disease with intolerance or contraindication: Mild to moderate disease and intolerance or contraindication to methotrexate, leflunomide, or another conventional synthetic drug such as sulfasalazine.
      • Enthesitis or predominantly axial disease: Mild to moderate disease with enthesitis or predominantly axial disease.
      • Severe disease: The member has severe disease.

    Ankylosing spondylitis and non-radiographic axial spondyloarthritis initial therapy

    Authorization of 12 months may be granted for adult members with active ankylosing spondylitis or active non-radiographic axial spondyloarthritis when either pathway is met.

    Axial spondyloarthritis initial pathways

    • Prior therapy: Previously received a biologic or targeted synthetic drug indicated for active ankylosing spondylitis or active non-radiographic axial spondyloarthritis, such as Rinvoq or Xeljanz.
    • NSAID pathway

      • Inadequate response to at least two nonsteroidal anti-inflammatory drugs.At least two NSAIDs
      • Intolerance or contraindication to two or more nonsteroidal anti-inflammatory drugs.Two or more NSAIDs

    Hidradenitis suppurativa initial therapy

    Authorization of 12 months may be granted for adult members with moderate to severe hidradenitis suppurativa when either pathway is met.

    Hidradenitis suppurativa initial pathways

    • Prior biologic therapy: Previously received a biologic indicated for treatment of moderate to severe hidradenitis suppurativa.
    • Oral-antibiotic pathway

      • Inadequate response to an oral antibiotic used for hidradenitis suppurativa for at least 8 weeks, such as clindamycin, metronidazole, moxifloxacin, rifampin, or a tetracycline.At least 8 weeks
      • Intolerance or contraindication to oral antibiotics used for the treatment of hidradenitis suppurativa.

    Initial therapy requirements

    Before treatment initiation, both requirements must be satisfied for every covered indication.

    Universal initial therapy requirements

    • TB evaluation: The member has been evaluated for tuberculosis infection before initiation of treatment with a biologic or targeted synthetic drug associated with an increased risk of TB.
    • No concomitant same-indication therapy: The requested medication is not used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    Ankylosing spondylitis and non-radiographic axial spondyloarthritis continuation

    Authorization of 12 months may be granted for adult members, including new members, using Bimzelx for ankylosing spondylitis or non-radiographic axial spondyloarthritis who achieve or maintain a positive clinical response.

    Axial spondyloarthritis continuation response: The member achieves or maintains low disease activity or improvement in signs and symptoms, with improvement from baseline in any of the following: functional status, total spinal pain, inflammation such as morning stiffness, swollen joints, tender joints, or C-reactive protein.

    Hidradenitis suppurativa continuation

    Authorization of 12 months may be granted for adult members, including new members, using Bimzelx for moderate to severe hidradenitis suppurativa who achieve or maintain a positive clinical response.

    Hidradenitis suppurativa continuation response: The member achieves or maintains low disease activity or improvement in signs and symptoms, with any of the following: reduction in abscess and inflammatory nodule count, reduced formation of new sinus tracts and scarring, decreased frequency of inflammatory lesions, reduced pain or suppuration, improved frequency of relapses, improved quality of life, or improvement on a disease severity assessment tool.
    Minimum oral-antibiotic trialAt least 8 weeks.
    Required treatment historyInadequate response to an oral antibiotic used to treat hidradenitis suppurativa.
    Examples of qualifying antibioticsClindamycin, metronidazole, moxifloxacin, rifampin, or tetracyclines.
    Alternative pathwayIntolerance or contraindication to oral antibiotics used to treat hidradenitis suppurativa.
    NSAID treatment history
    Inadequate response pathwayInadequate response to at least two nonsteroidal anti-inflammatory drugs (NSAIDs).
    Intolerance or contraindication pathwayIntolerance or contraindication to two or more NSAIDs.
    Applicable conditionsActive ankylosing spondylitis or active non-radiographic axial spondyloarthritis.
    Prior Authorization

    Qualified Prescriber Required

    Bimzelx must be prescribed by or in consultation with a qualified specialist for the applicable indication.

    • Plaque psoriasis: dermatologist.
    • Psoriatic arthritis and hidradenitis suppurativa: rheumatologist or dermatologist.
    • Ankylosing spondylitis and non-radiographic axial spondyloarthritis: rheumatologist.

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Unsupported block type: step_therapy

    Unsupported block type: step_therapy

    Unsupported block type: step_therapy

    Unsupported block type: step_therapy

    Unsupported block type: prior_auth

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: billing_rule

    Denial Risk

    Uncovered Indication

    Requests for indications outside the covered FDA-approved indications are considered experimental or investigational and are not medically necessary.

    • Covered indications are plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa, subject to the applicable criteria.
    Denial Risk

    Missing Tuberculosis Evaluation

    Authorization may be denied when the required pre-treatment tuberculosis evaluation is not documented.

    • Confirm and retain evidence of TB evaluation before treatment initiation.
    Denial Risk

    Concomitant Biologic or Targeted Synthetic Therapy

    Coverage is not available for Bimzelx used with another biologic drug or targeted synthetic drug for the same indication.

    • Do not submit or continue same-indication combination therapy without addressing the prohibited concomitant treatment.
    Denial Risk

    Dosing Outside Accepted Limits

    Dosing outside FDA-approved labeling, accepted compendia, or evidence-based practice guidelines may result in denial or limitation of coverage.

    • Verify the requested dose, frequency, and duration against accepted dosing standards.
    Denial Risk

    Concurrent Same-Indication Therapy

    Coverage may be denied when Bimzelx is requested concurrently with another biologic or targeted synthetic therapy for the same indication.

    • Reconcile active biologic and targeted synthetic therapies before submitting the request.
    Denial Risk

    TB Safety Requirement Before Treatment

    A tuberculosis evaluation must occur before initiation of Bimzelx when treatment carries an increased risk of TB infection.

    • This safety requirement applies to all indications.